

CLAIMS

What is claimed is:

1. A medicament comprising a recombinant poxvirus which is genetically engineered to be incapable of expressing a native A41L protein, together with a pharmaceutically acceptable carrier for use in treatment or prophylaxis.
2. A detection method comprising the steps of:
 - a) providing a chemokine-binding molecule which is an A41L protein or a chemokine-binding fragment thereof;
 - b) contacting the chemokine-binding molecule with a sample;
 - c) detecting an interaction of the chemokine-binding molecule with a chemokine in the sample.
3. The detection method according to claim 2, for detecting the presence of one or more chemokines in a biological sample.
4. The detection method according to claim 2, for detecting one or more chemokines in the CXC group of chemokines.
5. The detection method according to claim 2, for detecting at least one IFN- γ -induced chemokine such as Mig or IP-10.
6. The detection method according to claim 2, wherein the chemokine-binding molecule is immobilised on a solid support.